Study supports launch of Phase I clinical trial to test a designer DNA agent — an antisense oligonucleotide that targets a gene called IRF4 — in patients with multiple myeloma
Heather Buschman, PhD
Advertisement
Articles by Heather Buschman, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Zidesamtinib in Pretreated ROS1+ NSCLC
2
Dr Patel on the Unmet Need in EGFR+ Transformed Small Cell Lung Cancer
3
Dr Galsky on Systemic Therapy Advances in Muscle-Invasive Bladder Cancer
4
Dr Cooper on Biomarker Selection for DLL3-Targeted Therapies in ES-SCLC
5